Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1

Conditions

Carcinoma, Hepatocellular 1

Interventions

Gemcitabine 302Fluorouracil 296Oxaliplatin 269Bevacizumab 267Capecitabine 233Leucovorin 229pembrolizumab 215Irinotecan 185Cisplatin 142Cetuximab 142Nivolumab 131Paclitaxel 117130-nm albumin-bound paclitaxel 117Sorafenib 86Albumin-Bound Paclitaxel 75Docetaxel 65regorafenib 64atezolizumab 64IFL protocol 61Folfox protocol 61Trastuzumab 55Panitumumab 47durvalumab 46Ramucirumab 43Injections 43Sunitinib 41Drug Therapy 41Carboplatin 40trifluridine tipiracil drug combination 38lenvatinib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Population Groups × Gastrointestinal × Clear all
NCT05352646 2023-09-28

NewishT Cell Therapy for HCC With High Risk of Recurrence After Radical Resection

Newish Technology (Beijing) Co., Ltd.

Phase 1 Unknown
26 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡